Current Report Filing (8-k)
January 06 2022 - 9:01AM
Edgar (US Regulatory)
0001441693
false
0001441693
2021-12-30
2021-12-30
0001441693
dei:FormerAddressMember
2021-12-30
2021-12-30
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
DC 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the
Securities
Exchange Act of 1934
Date
of report (Date of earliest event reported): December 30, 2021
MARRONE
BIO INNOVATIONS, INC.
(Exact
Name of Registrant as Specified in Charter)
Delaware
|
|
001-36030
|
|
20-5137161
|
(State
or Other Jurisdiction
of
Incorporation)
|
|
(Commission
File
Number)
|
|
(I.R.S.
Employer
Identification
No.)
|
7780-420
Briar Creek Parkway,
Raleigh,
NC 27617
(Address
of Principal Executive Offices, and Zip Code)
(530)
750-2800
Registrant’s
Telephone Number, Including Area Code
1540
Drew Avenue, Davis, CA 95618
(Former
Name or Former Address, if Changed Since Last Report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions (see General Instruction A.2. below):
|
☐
|
Written
communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
|
|
☐
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
|
|
☐
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
|
|
☐
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class
|
|
Trading
Symbol(s)
|
|
Name
of each exchange on which registered
|
Common
Stock, $0.00001 par value
|
|
MBII
|
|
Nasdaq
Capital Market
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2 of this chapter).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item
1.01. Entry into a Material Definitive Agreement.
Amendment
to Amended Inventory Financing Addendum
On
December 30, 2021, Marrone Bio Innovations, Inc. (the “Company”) entered into a First Amendment (the “Amendment”)
to the Company’s Amended Inventory Financing Addendum (the “Addendum”) dated as of January 6, 2020 with LSQ Funding
Group, L.C. (“LSQ”).
The
Amendment increases the maximum amount the Company is allowed to request as an advance under the Addendum from $3,000,000 to $4,500,000.
Following this Amendment, the Addendum allows the Company to request an advance up to the lesser of (i) 100% of the Company’s unpaid
finished goods inventory; (ii) 65% of the appraised value of the Company’s inventory performed on or on behalf of LSQ; or (iii)
$4,500,000. All other terms of the Addendum remain unchanged.
The
Amendment and the Addendum are filed herewith as Exhibits 10.1 and 10.2, respectively, and are incorporated herein by reference, and
the foregoing descriptions are qualified in their entirety by the terms contained therein.
Item
2.03. Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.
The
information set forth in Item 1.01 of this Current Report on Form 8-K is incorporated by reference into this Item 2.03.
Item
8.01. Other Events.
On
January 6, 2022, the Company issued a press release announcing the Amendment. A copy of the press release is attached hereto as Exhibit
99.1.
Item
9.01. Financial Statements and Exhibits.
Signature
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
MARRONE
BIO INNOVATIONS, INC.
|
|
|
Date:
January 6, 2022
|
By:
|
/s/
Linda V. Moore
|
|
Name:
|
Linda
V. Moore
|
|
Title:
|
Executive
Vice President, General Counsel, Secretary and Chief Compliance Officer
|
Marrone Bio Innovations (NASDAQ:MBII)
Historical Stock Chart
From Jun 2024 to Jul 2024
Marrone Bio Innovations (NASDAQ:MBII)
Historical Stock Chart
From Jul 2023 to Jul 2024